Boston Scientific Corp (NYSE:BSX)
| 54.93 BATS BZX Real-Time Price As of 2:09pm ET |  +0.05 / +0.09%Today’s Change | 44.35 Today|||52-Week Range 56.22 | +18.72% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Year Trend | |||||
|---|---|---|---|---|---|---|
2015 | 2016 | 2017 | 2018 | |||
| Operating Activities | Net Income / Starting Line | -239.0M | 347.0M | 104.0M | 1.7B | |
| Depreciation | 769.0M | 815.0M | 844.0M | 894.0M | ||
| Total Other Cash Flow | 322.0M | -186.0M | 412.0M | -95.0M | ||
| Funds From Operations | 320.0M | 976.0M | 1.4B | 2.5B | ||
| Funds From/For Other Operating Expenses | -280.0M | 4.0M | -66.0M | 2.2B | ||
| Net Cash Flow - Operating Activities | 600.0M | 972.0M | 1.4B | 310.0M | ||
| Investing | Increase In Investments | -266.0M | -132.0M | -131.0M | -172.0M | |
| Decrease In Investments | 61.0M | 0.00 | 0.00 | 0.00 | ||
| Capital Expenditures | -247.0M | -376.0M | -319.0M | -316.0M | ||
| Fixed Asset Disposal | 0.00 | 29.0M | 0.00 | 15.0M | ||
| Net Assets From Acquisitions | -1.7B | -408.0M | -560.0M | -1.4B | ||
| Net Cash Flow Investing | -2.2B | -887.0M | -1.0B | -1.9B | ||
| Financing | Short Term Borrowings | 0.00 | 0.00 | 1.2B | 1.0B | |
| Long Term Borrowings | 3.1B | 630.0M | 2.2B | 1.6B | ||
| Long Term Debt Reduction | -1.7B | -820.0M | -3.2B | -1.2B | ||
| Net Proceeds Stock Sale | 114.0M | 111.0M | 85.0M | 101.0M | ||
| Common Preferred Redeemed | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Common Dividends | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Cash Dividends Paid - Total | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Sources - Financing | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Uses - Financing | 222.0M | 127.0M | 98.0M | 74.0M | ||
| Net Cash Flow - Financing | 1.3B | -206.0M | 110.0M | 1.4B | ||
| Exchange Rate | Effect of Exchange Rate on Cash | -4.0M | -2.0M | 4.0M | -8.0M | |
| Net Change In Cash | -264.0M | -121.0M | 526.0M | -179.0M | ||
